- $65.92m
- -$14.71m
- 14
- 22
- 37
- 14
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.46 | ||
| Price to Tang. Book | 1.46 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -179.04% | ||
| Return on Equity | -115.68% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 5.2 | 0.43 | 0.25 | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Directors
- Jay Short CHM (63)
- Scott Smith PRE (58)
- Richard Waldron CFO (67)
- Christian Vasquez VFN (45)
- Eric Sievers OTH (57)
- Edward Williams DRC (65)
- Priyanka Belawat IND (41)
- Mary Gray IND (68)
- Guy Levy IND (39)
- Susan Moran IND (51)
- Lawrence Steinman IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 15th, 2019
- Public Since
- December 16th, 2020
- No. of Shareholders
- 28
- No. of Employees
- 65
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 48,115,918
- Address
- 11085 Torreyana Road, SAN DIEGO, 92121
- Web
- https://www.bioatla.com/
- Phone
- +1 8585580708
- Contact
- Richard Waldron
- Auditors
- Ernst & Young LLP
Upcoming Events for BCAB
Q3 2024 Bioatla Inc Earnings Release
Similar to BCAB
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Bioatla share price?
As of Today at 19:37 UTC, shares in Bioatla are trading at $1.51. This share price information is delayed by 15 minutes.
How has the Bioatla share price performed this year?
Shares in Bioatla last closed at $1.51 and the price had moved by -59.41% over the past 365 days. In terms of relative price strength the Bioatla share price has underperformed the S&P500 Index by -67.7% over the past year.
What are the analyst and broker recommendations for Bioatla?
The overall consensus recommendation for Bioatla is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Bioatla dividend yield?
Bioatla does not currently pay a dividend.
Does Bioatla pay a dividend?
Bioatla does not currently pay a dividend.
When does Bioatla next pay dividends?
Bioatla does not currently pay a dividend.
How do I buy Bioatla shares?
To buy shares in Bioatla you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Bioatla?
As of the previous close price of $1.51, shares in Bioatla had a market capitalisation of $72.66m.
Where are Bioatla shares listed?
Here are the trading details for Bioatla:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BCAB
What kind of share is Bioatla?
Based on an overall assessment of its quality, value and momentum Bioatla is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Bioatla share price forecast for 2024?
The analyst consensus target price for shares in Bioatla is $9.75. That is 545.7% above the last closing price of $1.51.
Analysts covering Bioatla currently have a consensus Earnings Per Share (EPS) forecast of -$1.61 for the next financial year.
What is the trend in the Bioatla share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioatla. Over the past six months, its share price has underperformed the S&P500 Index by -40.84%.
As of the last closing price of $1.51, shares in Bioatla were trading -31.36% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Bioatla PE Ratio?
The Bioatla PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.51.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Bioatla?
Bioatla's management team is headed by:
- Jay Short - CHM
- Scott Smith - PRE
- Richard Waldron - CFO
- Christian Vasquez - VFN
- Eric Sievers - OTH
- Edward Williams - DRC
- Priyanka Belawat - IND
- Mary Gray - IND
- Guy Levy - IND
- Susan Moran - IND
- Lawrence Steinman - IND